Table 1.
Characteristics of the enrolled participants.
| Primary biliary cholangitis | Disease controls | Healthy controls | |
|---|---|---|---|
| (n = 42) | (n = 25) | (n = 30) | |
| Age (years old) | 58 (30–76) | 51 (27–69) | 53 (25–67) |
| Female gender (n, %) | 39, 92.9% | 21, 84.0% | 26, 86.7% |
| Alanine aminotransferase | 29.5 (9.0–251.0) | 46.0 (13.0–182.0) | 12.0 (2.0–16.0) |
| Aspartate aminotransferase | 41.0 (16.0–198.0) | 24.0 (16.0–124.0) | 19.0 (11.0–36.0) |
| Alkaline phosphatase | 133.5 (55.0–909.0) | 121.0 (53.0–708.0) | 62.0 (30.0–89.0) |
| γ-glutamyl transpeptidase | 69.5 (11.0–745.0) | 57.0 (20.0–624.0) | 17.0 (3.2–29.0) |
| Total bilirubin | 14.0 (4.9–74.7) | 11.3 (6.3–57.2) | 7.0 (2.1–16.0) |
| Direct bilirubin | 4.7 (1.4–44.2) | 5.5 (1.9–35.0) | 1.5 (0.6–5.4) |
| Total bile acid | 9.70(1.4–436.9)† | 8.8 (0.5–303.3) | 2.7 (1.2–9.0) |
| Albumin | 43.0 (27.0–48.0) | 46.5 (41.0–50.0) | 31.0 (23.0–50.0) |
| Immunoglobulin G | 15.2 (8.5–33.2)‡ | 15.7 (10.4–24.5) | 12.0 (8.8–16.7) |
| Immunoglobulin A | 2.8 (0.3–5.4)‡ | 2.8 (1.6–3.2) | 2.1 (0.5–3.9) |
| Immunoglobulin M | 2.1 (0.6–8.5)‡ | 1.2 (0.7–2.0) | 1.4 (0.5–2.3) |
| Platelet count | 230 (51–305)* | 242 (115–376) | ND |
| Aspartate aminotransferase to platelet ratio | 0.7 (0.2–2.6)* | 0.4 (0.2–1.0) | ND |
| Anti-mitochondrial antibody positive (n) | 38 | 0 | 0 |
| Anti-gp210 antibody positive (n) | 11§ | 0 | ND |
| Anti-sp100 antibody positive (n) | 4§ | 0 | ND |
All the PBC patients were undergo ursodeoxycholic acid treatment only. Data were depicted as Median (Min, Max) otherwise. Reference interval: Alanine aminotransferase: 7–40 U/L; Aspartate aminotransferase: 13–35 U/L; Alkaline phosphatase: 35–100 U/L; γ-glutamyl transpeptidase: 7–45 U/L; Total bilirubin: 5.1–22.2 μmol/L; Direct bilirubin: 0–6.8 μmol/L; Total bile acid: <10 μmol/L; Albumin: 35–52 g/L; Immunoglobulin G: 7–17 g/L; Immunoglobulin A: 0.7–4 g/L; Immunoglobulin M: 0.4–2.3 g/L; Platelet: 100–350 × 109/L; Anti-mitochondrial antibody: <1:80; Anti-gp210 antibody: Negative; Anti-sp100 antibody: Negative. Available in 39 PBC patients; Available in 32 PBC patients; *Available in 35 PBC patients; §Available in 23 PBC patients. ND, not detected.